Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

American Heart Journal

Volumn 170, Issue 5, 2015, Pages 845-854

  Chen, Wei Ren ^a   Hu, Shun Ying ^a   Chen, Yun Dai ^a   Zhang, Ying ^a   Qian, Geng ^a   Wang, Jing ^a   Yang, Jun Jie ^a   Wang, Zhi Feng ^a   Tian, Feng ^a   Ning, Qing Xiu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; FIBRINOGEN RECEPTOR ANTAGONIST; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIRAGLUTIDE; MALONALDEHYDE; NITRIC OXIDE; PLACEBO; SUPEROXIDE DISMUTASE; TROPONIN T;

ACUTE PANCREATITIS; ADULT; ARTICLE; BLOOD VESSEL FUNCTION; CARDIAC PATIENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELUTING CORONARY STENT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOTHELIAL FUNCTION; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLAMMATION; INTERVENTION STUDY; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; ULTRASOUND TRANSDUCER; VOMITING; DOSE RESPONSE; DRUG EFFECTS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART STROKE VOLUME; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PREOPERATIVE CARE; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84954235632     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.07.014     Document Type: Article

References (39)

1. E.C. Keeley, J.A. Boura, and C.L. Grines Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials Lancet 361 2003 13 20
2. D. Aronson, H. Hammerman, M.R. Kapeliovich, and et al. Fasting glucose in acute myocardial infarction: incremental value for long-term mortality and relationship with left ventricular systolic function Diabetes Care 30 2007 960 966
3. A. Ceriello, A. Novials, E. Ortega, and et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes Diabetes Care 36 2013 2346 2350
4. L. Timmers, J.P. Henriques, D.P. de Kleijn, and et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury J Am Coll Cardiol 53 2009 501 510
5. M.H. Noyan-Ashraf, M.A. Momen, K. Ban, and et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice Diabetes 58 2009 975 983
6. L.A. Nikolaidis, S. Mankad, G.G. Sokos, and et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 2004 962 965
7. J.S. Woo, W. Kim, S.J. Ha, and et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study Arterioscler Thromb Vasc Biol 33 2013 2252 2260
8. J. Lønborg, N. Vejlstrup, H. Kelbæk, and et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction Eur Heart J 33 2012 1491 1499
9. W. Ganz The thrombolysis in myocardial infarction (TIMI) trial N Engl J Med 313 1985 1018 [PMID: 3930960]
10. A.W. van 't Hof, A. Liem, H. Suryapranata, and et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group Circulation 97 1998 2302 2306
11. G. Niccoli, F. Burzotta, L. Galiuto, and et al. Myocardial no-reflow in humans J Am Coll Cardiol 54 2009 281 292
12. Workgroup on Hypoglycemia, and American Diabetes Association Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia Diabetes Care 28 2005 1245 1249
13. A.S. Levey, L.A. Stevens, C.H. Schmid, and et al. A new equation to estimate glomerular filtration rate Ann Intern Med 150 2009 604 612
14. P.J. Best, D.N. Reddan, P.B. Berger, and et al. Cardiovascular disease and chronic kidney disease: insights and an update Am Heart J 148 2004 230 242
15. W.L. Miller, R.S. Wright, J.P. Grill, and et al. Improved survival after acute myocardial infarction in patients with advanced Killip class Clin Cardiol 23 2000 751 758
16. M. Parks, and C. Rosebraugh Weighing risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy N Engl J Med 362 2010 774 777
17. S.R. Ahmad, and J. Swann Exenatide and rare adverse events N Engl J Med 358 2008 1970 1971
18. K. Kikugawa, T. Kojima, S. Yamaki, and et al. Interpretation of the thiobarbituric acid reactivity of rat liver and brain homogenates in the presence of ferric ion and ethylenediaminetetraacetic acid Anal Biochem 202 1992 249 255
19. G.A. Oswald, S. Corcoran, and J.S. Yudkin Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction Lancet 1 1984 1264 1267
20. R. Marfella, M. Siniscalchi, K. Esposito, and et al. Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome Diabetes Care 26 2003 3129 3135
21. J. Wichmann, M. Ketzel, T. Ellermann, and et al. Apparent temperature and acute myocardial infarction hospital admissions in Copenhagen, Denmark: a case-crossover study Environ Health 11 2012 19 [PMID: 22463704]
22. J.J. Dinicolantonio, A.K. Niazi, M.F. McCarty, and et al. L-carnitine for the treatment of acute myocardial infarction Rev Cardiovasc Med 15 2014 52 62
23. N.B. Perepech, A.O. Nedoshivin, and I.V. Nesterova Neoton and thrombolytic therapy of myocardial infarction Ter Arkh 73 2001 50 55
24. P. García-Hernández, R. Arechavaleta-Granell Mdel, J. Yamamoto, and et al. Liraglutide and glimepiride on glycaemic control in type 2 diabetes in the Mexican cohort (LEAD 3) Rev Med Inst Mex Seguro Soc 48 2010 543 548
25. S. Matsumoto, M. Yamazaki, M. Kadono, and et al. Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes J Clin Biochem Nutr 53 2013 68 72
26. M.A. Nauck, N. Kleine, C. Orskov, and et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 1993 741 744
27. J. Lønborg, H. Kelbæk, N. Vejlstrup, and et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia Circ Cardiovasc Interv 5 2012 288 295
28. L.M. McCormick, A.C. Kydd, P.A. Read, and et al. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease Circ Cardiovasc Imaging 7 2014 274 281
29. A. Undas, I. Wiek, E. Stêpien, and et al. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome Diabetes Care 31 2008 1590 1595
30. J.Y. Park, N. Takahara, A. Gabriele, and et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation Diabetes 49 2000 1239 1248
31. J.W. Wang, Y.D. Chen, C.H. Wang, and et al. Development and validation of a clinical risk score predicting the no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction Cardiology 124 2013 153 160
32. C.H. Wang, Y.D. Chen, X.C. Yang, and et al. The effect of admission hyperglycemia on coronary reflow in primary percutaneous coronary intervention Zhonghua Nei Ke Za Zhi 50 2011 303 306
33. P.A. Read, F.Z. Khan, and D.P. Dutka Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease Heart 98 2012 408 413
34. M.L. Villanueva-Peñacarrillo, J. Puente, A. Redondo, and et al. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models Endocrine 15 2001 241 248
35. T. Zhao, P. Parikh, S. Bhashyam, and et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts J Pharmacol Exp Ther 317 2006 1106 1113
36. S.C. Bekkers, S.K. Yazdani, R. Virmani, and et al. Microvascular obstruction: underlying pathophysiology and clinical diagnosis J Am Coll Cardiol 55 2010 1649 1660
37. B.B. Dokken, L.R. La Bonte, G. Davis-Gorman, and et al. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents Horm Metab Res 43 2011 300 305
38. M.H. Noyan-Ashraf, E.A. Shikatani, I. Schuiki, and et al. A glucagon-like Peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity Circulation 127 2013 74 85
39. Y. Hattori, T. Jojima, A. Tomizawa, and et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells Diabetologia 53 2010 2256 2263